MedTrace Logo

Study of XmAb412 in Healthy Participants

NCT07713485 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2026-08-03

No results posted yet for this study

Summary

This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants

Conditions

  • Not Applicable - Healthy Adult Participants

Interventions

DRUG

XmAb412 Monoclonal Bispecific Antibody

Monoclonal Bispecific Antibody

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • 412 Study Information · Xencor, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-13
Primary Completion
2027-05-31
Completion
2028-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07713485 on ClinicalTrials.gov